Last reviewed · How we verify
NCT03882827
Natural History of Duchenne Muscular Dystrophy
trial in Duchenne Muscular Dystrophy in 220 participants. Currently enrolling.
30 May 2029
Quick facts
| Lead sponsor | Genethon |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 220 |
| Start date | 19 December 2019 |
| Primary completion | 30 May 2029 |
| Estimated completion | 30 September 2029 |
| Sites | 15 locations across Belgium, France, United Kingdom, Spain |
Conditions studied
- Duchenne Muscular Dystrophy — all drugs for Duchenne Muscular Dystrophy →
Sponsor
Genethon — full company profile →
Who can join
Adults 4 to 9, male only, with Duchenne Muscular Dystrophy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Baseline Study on Duchenne Muscular Dystrophy (DMD) in view to collect data on the natural disease course in a cohort in young male subjects aged from 4 to 9 Years over a period of 6 to 36 months using disease appropriate evaluations.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Of rAAV and Men: From Genetic Neuromuscular Disorder Efficacy and Toxicity Preclinical Studies to Clinical Trials and Back.
Buscara L, Gross DA, Daniele N. · · 2020 · cited 19× · PMID 33260623 · DOI 10.3390/jpm10040258 -
Current and Emerging Therapeutic Strategies for the Treatment of Duchenne Muscular Dystrophy.
Lopez Perez MA, Weisleder NL. · · 2026 · PMID 42194990 · DOI 10.3390/genes17050533
Verify or expand the search:
- PubMed search for NCT03882827
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Duchenne Muscular Dystrophy
Currently open trials in the same condition.
- NCT07287189 — Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients · Phase 2 · recruiting
- NCT06817382 — A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Ma · Phase 1 · recruiting
- NCT06402942 — Gamified Occupational Therapy for Adolescents With Duchenne Muscular Dystrophy · NA · recruiting
- NCT06450639 — A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD) · Phase 2 · active not recruiting
- NCT06692426 — Trial of Cell Based Therapy for DMD · Phase 1 · recruiting
Other Genethon trials
Trials by the same sponsor.
- NCT06518005 — Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome · Phase 2 · recruiting
- NCT03842878 — Natural History Study of Patients With Limb-Girdle Muscular Dystrophy 2I · completed
- NCT03466463 — Gene Therapy for Severe Crigler Najjar Syndrome · NA · recruiting
- NCT02757911 — Gene Therapy for X-linked Chronic Granulomatous Disease · Phase 1, PHASE2 · terminated
- NCT01855685 — Gene Therapy for X-linked Chronic Granulomatous Disease (X-CGD) · Phase 1, PHASE2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03882827 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Genethon
- Last refreshed: 12 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03882827.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing